#+OPTIONS: H:12
* antibiotics :l:
** Cell Wall Biosynthesis
*** Beta-lactam antibiotics
**** Why do β-lactam antibiotics inhibit penicillin-binding proteins (transpeptidase)?
(D-Ala)₂ looks a lot like penicillin, so PBP-Serine-OH reacts with penicillin instead of (D-Ala)₂ on the growing peptidoglycan polymer. β-lactam antibiotics irreversibly inhibit PBP.
**** rationale for combining with β-lactamase inhibitors
susceptibility to penicillinase
**** β-lactamase hydrolysis of penicillin
β-lactamase-Ser-OH opens β-lactam ring at carbonyl
**** resistance
***** causes
production of β-lactamase by bacteria
***** mechanism
β-lactamase hydrolyzes the β-lactam ring
**** SAR
***** overcoming resistance
- add bulky functional groups to the acyclic amide to sterically inhibit β-lactamases
- electron withdrawing group to acyclic amide
***** acid stability
- electron withdrawing group as substituent to acyclic amide
- adding acid stability allows the drug to have good oral bioavailability
***** both acid stability and β-lactamase resistance
sterically bulky /and/ electron withdrawing group substituted on the acyclic amide
**** classes :l:
***** Penicillins
****** TODO types by structure :l:
******* methicillin
******* isoxazole
******* ureidopenicillin
******* acidic penicillin
******* amino penicillin
****** Penicillin G/V
******* Pen G IV
******** common use
CNS manifestations of syphillis
******** syphillis—causative agent
Treponema pallidum
******* Pen G IM PCNs
******** common use
major Strep infections
******* Pen V PO
- strep throat
- some dental infections
****** semi-synthetic penicillins :l:
******* Naficillin
******** indication
nosocomial MSSA
******* Methicillin
******* Oxacillin
stable toward acid and β-lactamase
Bactocil
******** brand
******* Dicloxacillin
stable toward acid and β-lactamase
******** brand
- Dycill
- Pathocil
******* Amoxicillin/Ampicillin
******** coverage
- Strep. pneumo. and Intermediate S. pneumo in higher dosage
******** Ampicillin
- DOC for listeria
****** Acidic penicillins :l:
******* Ticarcillin
******** coverage
- Pseudomonas
- Gram-
****** “isoxazole penicillins”
- oxacillin
- dicloxacillin
****** Ureidopenicillins
******* Piperacillin
******** spectrum
- Pseudomonas aeruginosa
- Enterococcus
****** Aminopenicillins
******* ampicillin
******** indication
drug of choice for /Listeria/ infections
******* amoxicillin
******** prodrug
form with unionized amino groups, which would be ionized at physiological pH
****** MSSA
sensitive staph aureus (MSSA); this is /not MRSA/
******* practical uses
bactericidal against staph
****** questions
******* PO only?
- Penicillin V
******* IV only?
- Timentin
- Zosyn
****** physiochemical properties
******* acid-base attacks
acid-catalyzed ring opening of the strained Penam nucleus
******* pH environment
- Stable between 6-7.2
- Do not place in highly acidic or basic environment
****** combinations :l:
******* Amoxicillin + Clavulanic acid
******* Ticarcillin + Clavulanic Acid
******* Ampicillin + Sulbactam
******** brand
Unasyn
******* Piperacillin + Tazobactam
******** [#A] spectrum
- Pseudomonas aeruginosa
- Gram-(+)
- Gram-(-)
******** [#A] brand
Zosyn
****** [#A] mechanism of action
- bind transpeptidases (PBPs) to result in weak cell walls and bacterial lysis
- bactericidal
****** [#A] adverse effects
- hypersensitivity
- superinfections
- GI
- convulsions
***** Cephalosporins
****** general structure
[[./cephalosporin_general_structure.png]]
****** avoid with TPN or divalent metal ions
Ceftrioxone (Rocephin)
****** [#A] adverse effects
- renal toxicity
- hypoprothrombinemia
- thromboplebitis
****** SAR
******* free carboxylic acid at C2
- must be present for antibacterial activity
- prodrugs formed by making an ester with the carboxylic acid at C2 
****** 1st generation
******* Cefazolin
******** [#B] brand
Ancef
******** ROA
IV
******** indication
prophylaxis of Staphylococcus infection, esp. in surgery
******** spectrum
Gram-(+)
******* Cephalexin
******** brand
Keflex
******** ROA
PO
******** spectrum
- Gram-(+)
- modest activity against Gram-(-)
******* Cefadroxil
******** ROA
PO
******* Cephalothin
******** ROA
IV
****** 2nd generation
******* Cephamycins
******** [#A] common structural feature
7-methoxy group off the 3-cefem nucleus
******** spectrum
- certain anaerobic bacteria
- Bacteroides fragilis
******** drugs :l:
********* cefoxitin
********* cefotetan
********* cefmetazole
******* NON-cephamycins
******** indications
- COPD/bronchitis
- H. influenzae
******** drugs :l:
********* cefaclor
********** brand
Raniclor
********** ROA
PO
********* cefprozil
********** brand
Cefzil
********** ROA
PO
********* cefonicid
********* cefuroxime
********* cefoxitin
****** 3rd generation
******* common structural feature
2-amine-1,3-thiazole ring
******* ROA
parenteral
******* [#B] drugs
******** IV :l:
********* ceftriaxone 
********** [#B] brand
Rocephin
********** DOC for
Neisseria meningitis
********** usage
don’t administer within 24h of calcium products e.g. TPN
********* cefotaxime
********** [#B] brand
Claforan
********* ceftazidime
********** [#B] brand
- Fortaz
- Tazicef
********** coverage
- potent inducer of β-lactamase, especially in Enterobacter
- Pseudomonas
- Gram-(-) rods
******** “super hero gen” :l:
********* ceftazidime/avibactam
********** [#A] brand
Avycaz
********** [#A] spectrum
- ESBL
- MDR
- CRE
********** [#A] indication
- cIAI
- cUTI
********* ceftolozane/tazobactam
********** [#A] brand
Zerbaxa
********** [#A] indications
- cIAI
- cUTI
********** [#A] spectrum
- P. aeruginosa
- ESBL
- CRE
- MDR
******** PO :l:
********* cefixime
********* cefpoxoxime
********** brand
Vantin
********* cefdinir
********** brand
Omnicef
********* cefditore
********* ceftibute
********* cefoperazone
********* ceftizoxime
********** brand
Cefizox
****** 4th generation
******* drugs :l:
******** Cefepime
********* [#B] brand
Maxipime
****** 5th generation
******* drugs :l:
******** Ceftaroline
********* brand
- Teflaro
- Fosamil
********* ROA
IV
********* spectrum
- MRSA
- S. pneumoniae
- K. pneumoniae
- E. coli
***** Carbapenems
****** cilastin
inhibits renal dehydropeptidase-1, which hydrolyzes the β-lactam ring of imipenem
****** Imipenem + Cilastin
******* [#B] brand
Primaxin
******* [#A] rationale
inhibits renal dehydropeptidase
****** drugs :l:
******* Imipenem
******* Meropenem
******* Doripenem
******* Ertapenem
******** brand
Invanz
****** indications
- Basically covers everything (including anaerobes, atypicals, nasty GNRs, PA, etc).
- Ertapenem (Invanz) barely covers anything
****** non-indications
- MRSA
****** [#A] reasons for broad spectrum coverage
- improved penetration of porins
- enhanced binding to PBP (transpeptidase)
- increased resistance to β-lactamases
***** Carbacephems
***** Monobactams
****** drugs :l:
******* Aztreonam
******** ROA
IV
******** coverage
Gram-(-)
**** allergy
***** structures that cause reactivity
- β-lactam ring structure
- S on the β-lactam ring
- R1 group side chains
**** structures
***** [[./isoxazole_ring.png]]
isoxazole ring
***** [[./ampicillin.png]]
ampicillin
***** [[./cephalosporin_core_structure.png]]
cephalosporin
***** nuclei of each class
****** [[./cefem_nucleus.png]]
cefem nucleus
****** [[./penam_nucleus.png]]
penam nucleus
****** [[./monobactam_nucleus.png]]
monobactam nucleus
*** Glycopeptide :l:
**** Vancomycin
***** [#B] spectrum
- narrow
- Gram-(-) only
***** [#B] indications
- MRSA
- penicillin-resistant S. pneumniae
- susceptible Enterococci
***** [#B] adverse effects
- nephrotoxicity
- Redman’s syndrome
***** [#A] mechanism of action
- cell wall synthesis inhibitor
- blocks transpeptidase binding (peptidoglycan cross linking)
*** Glycolipopeptide :l:
**** Telavancin
**** Oritavancin
**** Dalbavancin
*** Miscellaneous
**** Cycloserine
***** side effects
CNS disturbances
***** MOA
- inhibits 2 key enzymes
  - D-alanine racemase
  - D-alanine synthase/ligase
- blocks peptidoglycan cross linking of the myobacterial cell wall
***** indication
TB infections
***** SAR
rigid analog of D-alanine
**** Isoniazid
***** indication
TB infections
**** Ethionamide
**** Ethambutol
**** Teicoplanin
**** fosfomycin
***** [#A] mechanism of action
- inhibits the synthesis of N-acetylmuramic acid
- cell wall synthesis inhibitor
*** Lipopeptides :l:
**** Daptomycin
***** [#A] MOA
- lipophillic decanoyl side chain inserts into bacterial cell membrane
- bactericidal
***** [#A] adverse effects
- myopathies (monitor CPK)
- interactions with statins
- eosinophillic pneumonia
***** indications
- MRSA
- penicillin-resistant S. pneumoniae
- vancomycin-resistant Enterococci and S. aureus
***** [#B] spectrum
- aerobic
- Gram-(+) only
***** [#A] monitoring
- CPK
- DDI with statins
**** Polymixins
***** MOA
- detergent-like effect
- loss of cell membrane integrity
- bactericidal
***** indications
- IV agent used to kill nasty infections
- Gram(-) bacteria
**** Bacitracin
***** [#B] spectrum
Gram(+)
***** [#A] mechanism of action
- cell wall synthesis inhibitor
- inhibits dephosphorylation of lipid carrier molecules that help build cell walls
***** formulation
- topical
- only available in combinations
  - with Polymyxin B (Polysporin™)
  - with Polymyxin B and Neomycin (Neosporin®)
**** Colistin
** Cytoplasmic Membrane 
** DNA Biosynthesis :l:
*** fluroquinolones
**** MOA
- inhibits topoisomerase II (DNA gyrase), which replicates, transcribes, and repairs bacterial DNA
- inhibits topoisomerase IV, which partitions DNA during cell division
- bactericidal
- concentration-dependent
**** structure
[[./fluroroquinolone_keto_enol_structure.png]]
**** SAR
****** CNS side effects
caused by a basic ring system substituent on C-7—pyrrolidine, piperazine, substituted piperazine, bicyclic ring system
****** C-3
must have a carboxylic acid at C-3
****** N-1
1,4-dihydroquinolone portion is essential because it freezes the drug in the correct keto-enol tautometer
****** chelation
- carboxylic acid at C-3
- keto at C-4
chelates divalent and trivalent cations; decreases oral bioavailability
****** fluorine subsitutent
******* at C-6
- good activity against Gram(-) bacteria
- broad spectrum activity
******* [#B] at C-6 and C-8
- improves drug absorption and half-life
- increases drug-induced photosensitivity
****** [#A] photosensitivity
lots of halogens (e.g., fluoro at C-8) trigger photosensitivity
**** drugs :l:
***** levofloxacin
****** brand
Levaquin
****** spectrum
- Gram(-)
- atypicals
- S. pneumoniae
- sensitive Staph.
***** gemifloxacin
****** indications
- very poor activity against Pseudomonas aeruginosa
****** spectrum
respiratory pathogens
***** moxifloxacin
****** brand
Avelox
****** indications
- respiratory pathogens, including S. pneumoniae
****** non-indicaations
UTIs
***** ciprofloxacin
****** [#B] brand
Cipro
****** spectrum
- enteric Gram(-) rods
- doesn’t cover
  - S. pneumoniae
****** indications
anthrax
****** non-indications
S. pneumoniae
***** norfloxacin
****** brand
Noroxin
****** indication
UTIs only
****** spectrum
Gram(-)
**** [#A] warnings
all quinolones should not be co-administered with tpn and divalent metal ions (because of the carboxylic acid plus the keto at the 4-position)
**** [#A] advantage in terms of spectrum of activity
active against intracellular/atypical
*** metronidzole
**** brand
Flagyl
*** nitrofurantoin
** folate synthesis inhibitors
*** dapsone
*** sulfonamides and trimethoprim
**** [#A] mechanism of action
- folic acid synthesis inhibitors
- bacteriostatic
**** [#A] spectrum (important organisms)
- Ricksettia
- P. aeruginosa
*** trimethoprim/sulfamethoxazole
** DNA-dependent RNA Polymerase
** RNA inhibitors :l:
*** rifamycins :l:
**** rifampin
**** rifabutin
**** rifapentine
** Protein Biosynthesis Inhibitors
*** 30S :l:
**** tetracyclines
***** [#A] mechanism of action
- reversible binding to 30S subunit of bacterial ribosome
- bacteriostatic
***** SAR
chelation of divalent and trivalent caations occur at C-{10, 11, 12}
***** drugs :l:
****** tetracycline
******* indication
skin and skin-structure infections in people ≥18 yo
******* class
glycylcycline
******* spectrum
- MSSA and MRSA
- Enterococcus faecalis (vancomycin-susceptible strains)
- Streptococcus species
- E. coli
- Bacteroides fragalis (an anaerobe)
****** doxyycline
******* ROA
- PO
- IV
******* spectrum
- aytpicals
  - Chlamydia
  - Chlamydophilia
  - M. pneumoniae
- tick borne diseases
  - Ehrlichia
  - Ricksettsoses
  - Vibrio cholerae, V. vulnificus
  - community associated MRSA
  - S. pneumniae
  - anthrax
****** minocycline
******* adverse effects
- dizziness
- vertigo
******* spectrum
community associated MRSA
******* indicaitons
- acne
- dental work
****** tigecycline
******* brand
Tygacil
******* ROA
IV only
****** ervacycline
****** omadacycline
***** [#A] adverse effects
- discoloration of developing teeth or bones
- gastroinestinal; pseudomembranous colitis caused by C. dificile
- photosensitvity
- CNS effects because its high lipid solubility allows it to enter CNS
***** mechanisms of resistance
- efflux of antibiotic from microbe
- decreased penetration into microbe
- bacterial production of a ribosome protective protein
**** [#C] aminoglycosides
***** [#A] MOA
- concentration-dependent bactericidal killing
- binds irreversibly to 30S ribosomal subunit, interfering with protein synthesis
***** [#A] combination with β-lactam antibiotics
- extends coverage to Gram-(+) pathogens
- synergy
- Viridians streptococcal infections or endocarditis
***** mechanisms of resistance
- phosphorylation of hydroxyl groups
- adenylation of hydroxyl groups
- acetylation of amino groups
***** [#B] spectrum
aerobic Gram-(-)
***** [#A] adverse effects
- ototoxicity
- nephrotoxicity
- neuromuscular blockade
***** drugs :l:
****** plazomicin
****** gentamicin
******* spectrum
- Gram-(-)
- P. aeruginosa
****** tobramycin
******* spectrum
P. aeruginosa
****** amikacin
******* spectrum
- high activity on nasty GNRs
- P. aeruginosa
****** streptomycin
***** toxicity
- nephrotoxicity
- ototoxicity
- neurotoxicity
***** combination
used /synergistically/ in combination with beta-lactam antibiotics or glycopeptides
*** 50S :l:
**** macrolides
***** drugs :l:
****** erythromycin
******* disadvantages
- acid catalyzed degradation in the stomach
- less than desirable bioavailability
- side effects
  - GI
  - hepatotoxicity
- significant resistance
****** clarithromycin
******* ROA
PO only
****** azithromycin
****** telithromycin
******* brand
Ketek
******* spectrum
macrolide-resistant pathogens including S. pneumoniae
******* toxicity
- hepatotoxicity
- prolongation of QTc interval
******* SAR
C-6 methoxy improves acid stability
****** fidaxomycin
******* brand
Dificid
******* spectrum
- narrow
- mainly used against C. dificile
***** structure
[[./macrolide_structure.png]]
***** [#A] MOA
- bacteriostatic
- reversible binding to 50S ribosomal subunit
***** non-indications
- respiratory tract infections---use alternative agents for Moraxella, atypical pneumonia organisms (Mycoplasma, Chlamyida, Legionella)
- use alternative agents for S. pneumoniae---erythromycin is resistant
***** indications
- acne
- dental infections
- H. influenzae infections
***** SAR
****** gut
intramolecular nucleophillic attack by hydroxyl on the carbonyl group results in an inactive drug
**** lincosamide
***** drugs :l:
****** clindamycin
******* brand
Cleocin
******* spectrum
- Gram-(+)
- MRSA
- Strep., esp. in patients allergic to beta-lactams
**** streptogramins
***** drugs :l:
****** quinupristin/dalfopristin
******* ROA
IV
******* spectrum
- MRSA
- VRSA
- VRE faecium---not /faecalis/
***** spectrum
Gram-(+)
**** oxazolidinones
***** drugs :l:
****** linezolid
******* [#A] brand
Zyvox
******* [#A] adverse effects
- hematologic toxicity
- serotonin syndrome
- GI intolerance
****** tedizolid
******* brand
Sivextro
***** warnings
- therapy more than 2 weeks increases risk of thrombocytopenia/pancytopenia
- not for use in endocarditis/endovascular infections
***** [#A] mechanism of action
- inhibits protein synthesis
- binds to 50S
- no cross-resistance with other drug classes
- bacteriostatic
**** nitro compounds
***** drugs :l:
****** nitrofurantoin
******* brand
- Macrodantin
- Macrobid
******* [#A] mechanism of action
- reactive intermediates attack ribosomal proteins, DNA, metabolic processes, and other macromolecules within the cell
- bactericidal
******* [#B] resistance
- doesn’t cause cross-resistance
- resistance emerges slowly
******* [#B] spectrum
- Gram-(+) and Gram-(-)
- /not/ P. aeruginosa, /not/ Proteus
******* [#B] adverse effects
- n/v/d, anorexia
- neuropathies
- hemolytic anemia
****** metronidazole
******* brand
Flaygyl
******* disulfiram-like reaction
abstain from alcohol during therapy for 72 hours post-therapy---metronidazole inhibits aldehyde dehydrogenase
******* indications
- Bacterioides fragilis
- Clostridium difficile colitis
- Heliobacter pylori
- Trichomonas vaginalis
- Amebiasis
- Giardiasis
****** tinidazole
******* brand
Tindamax
*** miscellaneous
**** mupirocin
***** [#A] mechanism of action
blocks synthesis of isoleucyl tRNA synthetase
** Tetrahydrofolic Acid
* lower respiratory infections
** community acquired pneumonia
*** diagnostics :l:
**** chest radiography (CXR)
- most common
- looks for
  - infiltrate
  - patchy consolidation
**** pretreatment blood cultures
test for etiology
**** biomarkers
- C-reactive protein (CRP)
- procalcitonin (PCT)
*** pathogens
- Chlamydophilla pneumoniae
- Legionella pneumophila
- Mycoplasma pneumoniae
- Haemophilus influenzae
- Streptococcus pneumoniae
*** assessment
**** CURB-65
- confusion : 1 point
- BUN ≥20 mg/dL : 1 point
- RR ≥30 bpm : 1 point
- SBP <90 mm Hg or DBP ≤60 mm Hg : 1 point
- age ≥65 : 1 point
*** treatment
**** categories
***** no antibiotic use in the past 3 months and previously healthy
- macrolide
- doxycycline
***** risk factors for drug-resistant /S. pneumoniae/ or comorbidities
- β-lactam + { macrolide, doxycyline }
- respiratory quinolone monotherapy
**** based on CURB-65 score
- 0-1: monotherapy in patients without cormobodities
- 2: combination antibiotics or quinolone; inpatient, no ICU admission
- 3-4: beta-lactam + {macrolide, quinolone}; also requires inpaatient ICU admission
** hospital acquired pneumonia
*** goal trough of vancomycin
15-20 mcg/mL
*** causative agents
- Pseudomonas sp.
- Acinetobacter sp.
- Escherichia sp.
- Klebsiella sp.
- Staphylococcus aureus
* gastrointestinal infections
** dystentery
- Y. enterocolitica 
- EHEC (Enterohemorrhagic E. coli)
- Campylobacter spp.
- Salmonella spp.
- Shigella spp.
** Guillain-Barre syndrome
C. jejuni
** HUS
*** acronym
hemolytc uremic syndrome
*** increases HUS risk
use of a fluoroquinolone or Bactrim may increase the risk of HUS by increasing production of Shiga-like toxin
** severe diarreha
>8 stools per day
** infectious diarrhea
*** treatment
**** fluid and electrolyte replacement
***** oral rehydration
Pedialyte, Rehydralyte, Infalyte, Oralyte, WHO formula
***** severe dehydration
****** definition
≥10% body weight loss
**** bismuth subsalicylate
***** brand
Pepto-Bismol
***** warnings
avoid in children because it may cause Reye’s syndrome
***** dosing
- 30 mL (2 tabs) q30-60min
- max 8 doses q24h
**** [#A] when antibiotic therapy recommended
- Severe diarrhea 
- Moderate-to-severe cases of traveler’s diarrhea
- Most cases of febrile dysenteric diarrhea
- Culture-proven bacterial diarrhea in high-risk patients
- Severe cases of cholera 
- ETEC 
- Pregnancy
- Immunocompromised patients
- Prolonged illnesses 
- Infants <3 months old
- Patients with fever and signs and symptoms of sepsis
**** watery diarrhea
***** ETEC
- Ciprofloxacin (Cipro) 750 mg PO x1
- azithromycin (Zithromax) 1000 mg PO OR 500 mg QD x3d
- rifamixin 200 mg PO TID x3
***** Vibrio cholerae
doxycycline 300 mg PO x1
**** dysenteric diarrhea
***** Campylobacter sp.
- azithromycin 500 mg PO QD x3d
- erythromycin 500 mg PO q6h x3d
***** Salmonella nontyphoidal, Shigella sp., Yersinia sp.
- Ciprofloxacin 750 mg PO QD
- Levofloxacin 500 mg PO QD
** traveler’s diarrhea
*** prophylaxis :l:
**** Bismuth subsalicyclate
***** brand
Pepto-Bismol
***** dosage
524 mg (2 tabs or 2 tbsp) PO QID
**** fluoroquinolones
**** doxycyline
**** azithromycin
**** rifaximin
200 mg pO TID only for Latin America and Africa
***** spectrum
only effective against E. coli
*** treatment
**** loperamide
***** brand
Immodium
***** indication
symptomatic relief
***** dose
4 mg x1 then 2 mg each subsequent stool; max 16 mg/day
**** empiric treatment
***** fluroquinolones
****** ciprofloxacin
****** levofloxacin
****** norfloxacin
800 mg PO x1d or 400 mg PO BID x3d
***** azithromycin
****** dose
1 g PO x1 or 500 mg PO QD x3
****** [#A] indication
South and Southeast Asia
***** Rifaximin
****** dose
200 mg PO TID x3
****** [#A] indication
- Latin America
- Jamaica
- Africa
- E. coli
** food poisoining
*** Enterotoxigenic poisonings
- Bacillus cereus
- Clostridium botuilism
- Clostridium perfringens (type A)
- Staphylococcus aureus
*** treatment options
- supportive care
- fluid replacement
- antimicrobials are not effective
* intra-abdominal infections
** pathophysiology
bacterial entry into and collections in the peritoneal or retroperitoneal spaces
*** pathogens to cover
**** peritonitis
***** primary
everything except anaerobes (i.e., Bacteroides)
*** TODO
cover e. coli for...
** etiology
*** GI microflora
**** stomach
- Streptococcus
- Lactobacillus
**** [#B] biliary tract
normally sterile
**** proximal small bowel
- Streptococcus
- E. coli
- Klebsiella
- Lactobacillus
- diptheroids
**** Distal ileum
- E. coli
- Klebsiella
- Enterobacter
- Bacteroides fragilis
- Clostridium
- peptostreptococci
- enterococci
**** colon
- Bacteroides spp.
- peptostreptococci
- Clostridium
- E. coli
- Klebsiella
- enterococci
- Enterobacter
- Candida
** [#B] peritonitis
*** primary
An infection of the peritoneal cavity without an evident source in the abdomen
**** causes
***** cirrhosis
alcohol abuse
***** ascites
- CHF
- malignancy
- systemic lupus erythematosus
- nephrotic syndrome
- hepatitis
***** bacterial
****** cirrhotic ascites
E. coli
****** peritoneal dialysis
- Gram-(+) coagulase-negative Staphylococci
  - S. aureus
  - S. streptococci
  - S. enterococci
- Gram-(-)
  - E. coli
  - Klebsiella spp.
  - Pseudomonas spp.
**** signs and symptoms
**** lab tests
- elevated WBC count
- ascitic fluid analysis
  - leukocyte count >250 PMNs/mm^3
  - gram stain
*** dialysis
staph and strep
*** secondary
A focal disease process in the abdomen
**** causes
- mechanical GI problems
- vascular causes
- trauma
- intraoperative events
- leakage from GI anastomosis
**** lab tests
- CBC with differential---in order to see bands
- Hct and BUN
*** tertiary
Infection that persists/ recurs 48h after adequate management of 1° or 2° peritonitis
** treatment
*** [#A] nonpharmacologic
- drainage procedures
- fluid therapy; crystalloids or colloids
- vasopressors
*** community-acquired complicated intra-abdominal inffections
**** [#B] mild-to-moderate infections
***** single agent
- Cefoxitin
- Moxifloxacin 400mg IV q24h
- Ertapenem 1g IV q24h
***** combination agents
- {cefalozin, cefuroxime, ceftriaxone, cefotaxime} + metronidazole 500mg IV q8h
- {ciprofloxacin 400mg IV q12h, levofloxacin 750mg IV q24h} + metronidazole 500mg IV q8h
**** [#B] high risk or high severity
***** single agent
- piperacillin-tazobactam
- carbapenem with Pseudomonas activity:
  - imipenem-cilastin
  - meropenem 1g IV q8h
  - doripenem
***** combination agents
- cefepime 2g IV q8-12h
- ceftazidime 2g IV q8h + metronidazole 500mg IV q8h
- {ciprofloxacin 400mg IV q12h, levofloxacin 750mg IV q24h} + metronidazole 500mg IV q8h
*** healthcare-acquired complicated intra-abdominal inffections
**** [#B] single agent
- piperacillin-tazobactam 3.375 IV q6h
- carbapenem with Pseudomonas activity
  - imipenem-cilastin
  - meropenem 1g IV q8h
  - doripenem
**** [#B] combination agents
- {Cefepime 2g IV q8-12h, ceftazidime 2g IV q8h} + metronidazole 500mg IV q8h
- β-lactam allergy: Aztreonam (Azactam) + vancomycin 15mg/kg IV q12h + metronidazole 500mg IV q8h
*** [#B] primary peritonitis
vancomycin + {cefepime-ceftazidime, imipenem-cilastin} for at least 1 week after the dialysate fluid is clear
*** acute cholecystitis and cholangitis
[[./treatment_for_acute_cholecystitis_and_cholangitis.png]]
*** [#B] anti-MRSA therapy
vancomycin

Empiric coverage for nosocoial intra-abdominal infectious patients known to be colonized or at risk of a MRSA infection due to significant, maybe failed, antibiotic exposure
*** use of aminoglycosides
**** reserved for specific patients
- infections due to multidrug-resistant Gram-(-) pathogens
- IgE-mediated allergic reactions
- complicated IAI
**** [#B] extended interval dosing
reasons for which are...
- /equivalent efficacy with less nephrotoxicity/
- concentration dependent killing
- long postantibiotic effect for Gram-(-) bacilli
*** [#A] when is it appropriate to discontinue anaerobic coverage
do not discontinue anaerobic therapy based on initial culture results because anaerobes are not identified until 4-7 days
** [#A] antimicrobial resistance
- ESBLs (extended-spectrum β-lactamases)
- cephalosporins
* urinary tract infections
** causative organisms
*** community-acquired :l:
**** E. coli
Gram-(-)
**** Staphylococcus saprophyticus
Gram-(+)
**** Proteus mirabilis
Gram-(-)
**** Klebsiella pneumoniae
Gram-(-)
**** Enterococcus faecalis
Gram-(+)
*** nosocomial-acquired :l:
**** E. coli
**** Enterococcus spp.
**** Klebsiella pneumoniae
**** Enterobacter spp.
**** Serratia spp.
**** Staphylococcus aureus
**** Pseudomonas aeruginosa
**** Candida spp.
** lab tests
*** urinalysis
1. midstream clean-catch method---preferred method
2. catheterization
3. suprapubic bladder aspiration
**** normal values
***** leukocytes
0-5 cells/mm^3
***** erythrocytes
0-2 cells/mm^3
***** crystals/casts
None
***** bacteria
None
***** epithelial cells
0-2 cells/mm^3
***** pH
4.5-8
***** specific gravity
1.003-1.03
** significant bacteriuria
*** females
- ≥100 CFU bacteria/mL in a symptomatic female
- ≥ 100’000 CFU noncoliforms/mL in a symptomatic female
*** males
≥10k CFU bacteria/mL in a symptomatic male
*** catheterized patients
any growth of bacteria on a suprapubic catheterization in a symptomatic patient
** cystitis
- lower urinary tract infection
- inflammation of the bladder, urethra, prostate, and epididymis
*** signs and symptoms
- Dysuria
- Frequency
- Urgency 
- Nocturia 
- Suprapubic heaviness 
- Hematuria (gross) 
- Fever usually absent 
*** treatment of complicated cystitis
*** treatment of acute uncomplicated cystitis
**** preferred :l:
***** nitrofurantoin monohydrate (Macrobid) 100 mg pO q12h x 5d
- avoid if CrCl <30 mL/min
- avoid if early pyelonephritis suspected
***** Bactrim DS 800-160 mg pO q12h x 3d
- avoid if resistance >20%
- used to treat UTI in past 3 months
***** Trimethoprim (Primsol) 100 mg pO q12h x 3d
avoid if CrCl <15 mL/min
***** fosfomycin (Monurol) 3 g PO x 1
avoid if early pyelonephritis suspected
**** alternative :ignore:
***** fluoroquinolones
***** β-lactams
- Augmentin 500-125 mg pO q8h x 5-7d
- cefdinir (Omnicef) 300 mg pO q8h x 5-7d
- cephalexin (Keflex) 500 mg pO q12h x 5-7d
- cefpodoxime (Vantin) 100 mg pO q12h x 5-7d
** pyelonephritis
- upper urinary tract infection
- inflammation of the kidney from infection
*** signs and symptoms
- Flank pain 
- Fever (>38.3 C or >100.9 F)
- Nausea/Vomiting 
- Malaise 
- Hematuria (gross)
*** acute pyelonephritis
**** treatment
- Cipro 400 mg IVPB q12h x 7d
- levofloxacin 500 mg ivpb q24h x 7d
- ampicillin/sulbactam (Unasyn) 3 g IVPB q6h
- piperacillin/tazobactam (Zosyn) 3.375 g IVPB q6h
**** signs and symptoms
- fever
- chills
- abdominal pain
- casts in urine
- leukocytosis
** treatment
*** relapse
- if relapse occurs within 90 days of treatment, NEVER use the same treatment regimen
- women who relapse after a 2 week course of therapy should receive another 2-4 weeks of therapy
*** recurrent
**** reinfection
- If reinfection occurs within 90 days of treatment, NEVER use the same treatment regimen
- use prophylactic therapy; Bactrim, TMP, nitrofurantoin, fluoroquinolones..., cephalexin
*** pregnancy
- avoid fluoroquinolones because they inhibit cartilage and bone development in newborns
- never use Bactrim in the 3rd trimester due to possible development of hyperbilirubinemia and kernicterus
- only use Bactrim in the 1st and 2nd trimesters
**** first trimester
- ends month 3
- weeks 9-13
**** second trimester
- ends month 6
- weeks 22-26
*** prostatitis
**** acute treatment
2-4 weeks:
- fluoroquinolones
- TMP
- cephalosporins
** drug-drug interactions
*** CYP450 inhibitors
SICKFACES.COM Group:
- S = sodium valproate 
- I = isoniazid 
- C = cimetidine 
- K = ketoconazole 
- F = fluconazole 
- A = alcohol – binge drinking 
- C = ciprofloxacin 
- E = erythromycin 
- S = sulfonamides 
- C = chloramphenicol 
- O = omeprazole 
- M = metronidazole 
- G = grapefruit juice 
*** CYP450 inducers
CRAP GPS
- C = carbamazepines 
- R = rifampin 
- A = alcohol – chronic 
- P = phenytoin 
- G = griseofulvin
- P = phenobarbitone 
- S = sulphylureas 
** questions
*** A patient diagnosed with a nosocomial-acquired UTI should be empirically treated for what microorganism? 
- Enterococcus faecalis 
- +Legionella pneumophila+
- +Streptooccous pyogenes+
- +Staphylococcus saprophyticus+
*** What lab result indicates the presence of cystitis on a urinalysis (UA)? 
- +Positive casts+
- +Positive epithelial cells+
- +Positive ketones+
- Positive WBC esterase
*** What patient should the use of nitrofurantoin be avoided? 
- A patient with a CrCl < 30 mL/min.
- +A patient with documented anaphylaxis to sulfa.+
- +A patient receiving daily warfarin.+
- +A patient who is pregnant and in her first trimester.+
*** SM presents to the ambulatory care clinic with symptoms of urinary frequency and burning. She was treated with Bactrim DS® 2-months ago for an uncomplicated UTI.  What is the preferred treatment for this patient? 
- +Bactrim DS PO Q12H x 3 days+
- +Ciprofloxacin 500 mg PO Q12H x 3 days+
- Fosfomycin 3 grams PO x 1 Dose
- +Nitrofurantoin 100 mg PO Q12H x 3 days+
* skin and soft tissue infections (SSTI)
** folliculitis
*** definition
Folliculitis is inflammation of the hair follicle
*** furnucles and carbuncles
** [#A] purulent vs. nonpurulent
*** purulent
- cellulitis
- abscess
- furuncle and carbuncle
*** nonpurulent
- cellulitis
- erysipelas
- necrotizing infection
** impetigo
*** definition
superficial skin infection, seen most commonly in children
*** causative organism
- S. aureus
- S. pyogenes
*** treatment
**** [#A] mainstay of therapy
mupirocin or retapmulin ointment BID x 5d
**** patients with numerous lesions and not responding to topicla therapy
anti-staphylocccal penicillins
** erysipelas
well-demarcated, superficial, erythematous infection affecting face and extremities
*** [#A] treatment
penicillin (IM or PO) x 7d; severe cases: IV penicillin
*** causative organism
Streptococcus pyogenes
** lymphangitis
*** definition
Inflammation involving the subcutaneous lymphatic channel
*** [#A] causative oragnism
- Group A streptococi---S. pyogenes
- S. aureus (esp. folliculitis)
*** treatment
- penicillin IV 1-2M units q4-6h
- clindamycin for penicillin allergic patients
** abscess/cellulitis
*** causative organism
- S. pyogenes
- S. aureus
*** treatment
**** purulent or underlying abscess
empiric coverage of MRSA
**** non-purulent diffuse cellulitis
empiric coverage for Streptococci sp.
** necrotizing fascitis
- high morbidity and mortality
- rare but aggressive subcutaneous infection
- causes major estruction of tissue
- early and aggressive surgical debridement
*** [#A] causative organism
Group A Streptococci---S. pyogenes
*** Type 1
polymicrobial infection---averager 5 different isolates per wound:
- Non-group A Strep: Enterobacteriaceae, Bacteriodes, Peptostreptococcus
- Saltwater viariant with marine vibrios (e.g., Vibrio vulnificus)
**** antimicrobial therapy
- (Ampicillin-sulbactam or piperacillin-tazobactam) + clindamycin + ciprofloxacin
- Carbapenem (meropenem, imipenem, ertapenem)
*** Type 2
monomicrobial infection caused by /S. pyogenes/ which may produce pyrogenic exotoxins
**** [#A] antimicrobial therapy
high dose penicillin (IV) + clindamycin (IV); *clindamycin* is for toxin suppression and superior efficacy
** animal bites
*** causative oragnism
Pasturella spp.
*** [#A] treatment
- oral: amoxicillin/clavulanate
- parenteral: ampicillin/sulbactam
** human bites
*** organism types
anaerobes
*** [#B] treatment
Augmentin 7-14d
*** prophylaxis
3-5d
** diabetic foot infection
*** causative organisms
- S. aureus including methicillin-resistant strains
- Streptococci
- Enterobacteriaceae
- Bacteriodes spp.
- Peptostreptococus spp.
- Pseudomonas aeruginosa
*** TODO pathogenesis
ischemia
* bone and joint infections
** osteomyelitis
*** [#A] diagnostics
- C-reactive protein (CRP)---predicts response to therapy; fluctuates sooner than ESR does
- Elevated erythrocyte sedimentation rate (ESR)
- MRI
*** [#A] cause
Staphylococcus aureus
*** [#B] monitoring parameters
- CRP or ESR
- WBC
- CBC
- culture and susceptibility
*** treatment
**** [#B] duration
- acute: >4-6 wks
- chronic: >6-12 wks
- 2-6 wks of IV with potential transition to PO to complete
**** Gram-(+) antibiotic therapy
***** [#B] definitive
****** MSSA
- naficillin or oxacillin 2g IV q4h
- cefazolin or ceftriaxone 2g IV q8h
****** MRSA
- linezolid
- continuation of empiric vancomycin therapy
***** empiric
****** [#A] preferred
vancomycin IV; troughs 15-20 mcg/mL
*** types
- puncture osteomyelitis
- contiguous osteomyelitis
- hemategenous osteomyelitis
** septic arthritis
*** [#A] most common pathogen
S. aureus
*** empiric treatment
**** [#A] adults
ceftriaxone 1 g {IV, IM} q24h
**** neonates and children :ignore:
- neonates: {naficillin, oxacillin} + cefotaxime
- children: naficillin, oxacillin, or cefalozin
* surgical prophylaxis / Surgical Site Infection (SSI)
** [#A] risk factors
- *diabetes*
- age
- obesity
- smoking
- malnutrition
** patient characteristics that may affect SSI
diabetic patients have increased risk for SSIs
** [#A] first line
Cefazolin 2 g; for patients weighing ≥ 120 kg, 3 g
** [#B] administration
- administer Cefazolin 1 hour before surgery
- discontinue 24 hours after surgery ends
** [#A] timing
- administer within 60 min prior to initial incision
- administer 2 hours before surgery for vancomycin and fluoroquinolones
** pharmacokinetics
*** [#C] half lives
1st gen cephalosporins: 1-2.2 hr
2nd gen cephalosporins: 0.7-4.6 hr
3rd gen cephalosporins: 5.4-10.9 hr
*** [#A] agents requiring redosing (because of short half lives)
- 1st gen cephalosporins
- 2nd gen cephalosporins
- aminopenicillins and β-lactamase inhibitor combinations
- aztreonam
- clindamycin
** [#B] pharmacodynamics
*** C_max:MIC
- aminoglycosides
- fluoroquinolones
- daptomycin
- colistin
*** AUC:MIC
- vancomycin
- macrolides
- tetracyclines
*** T>MIC (time during concentration higher than MIC)
β-lactams; dose more frequently
* Infective Endocarditis (IE)
** [#A] Risk factors
- prosthetic valve
- IVDU (IV drug abusers)
- heart disease
- transient bacteremia
  - GI procedures
  - GU procedures
  - dental procedures
** diagnosis
*** [#B] criteria
Definitive criteria:

- meeting Duke criteria
  - 2 major
  - 1 major + 3 minor
  - 5 minor
- microorganisms identified by culture or histologic examination
- active endocarditis confirmed by histologic examination

Duke criteria:
- major
  - positive blood culture (typical organism from at least 2 separate cultures)
  - evidence of endocardial involvement
- minor
  - risk factor
  - fever
  - vascular phenomena
  - immunologic phenomena
*** Duke criteria
**** major
- positive blood culture
- evidence of endocardial involvement
**** minor
- heart condition or IVDU
- fever
- vascular phenomena
- immunologic phenomena
- positive blood culture not meeting criteria
** [#A] causative organisms
- Staphylococci spp.
- Streptococci spp.
- Enterococci spp.
** drugs of choice
Streptococcal: penicillin G
Enterococcal: ampicillin
Staphylococcal: naficillin and oxacillin
** Enterococcal IE
*** preferred
- ampicillin + gentamicin
- penicillin G 18-30M units/day IV + gentamicin
- “double β-lactam”: ampicillin 2g IV q4h + ceftriaxone 2g IV q12h
*** chronic kidney disease
avoid aminoglycosides
** [#B] treatment
*** staphylococcal
**** native valve
***** oxacillin susceptible strains (MSSA)
- {naficillin, oxacillin} 2g IV q8h x 6wk
- cefazolin 2g IV q8h x 6wk
***** oxacillin resistant strains (MRSA)
- vancomycin 30 mg/kg in 2 divided doses x 6wk
- daptomycin ≥ 8 mg/kg/dose x 6wk
**** prosthetic valve
add rifampin for prosthetic valves
***** oxacillin susceptible (MSSA)
{naficillin, oxacillin} + rifampin + gentamicin
***** oxacillin resistant strains (MRSA)
vancomycin + rifampin + gentamicin
*** streptococcal (Viridians Strep. and S. gallolyticus)
- penicillin G 24M units IV q4h
- ceftriaxone 2g IV q24h
- ± gentamicin 3mg/kg IV q24h x 2wks (if penicillin sensitive)
4 weeks for native valves, 6 weeks for prosthetic
*** enterococcal
**** susceptible to penicillin or vancomycin
CrCl >50ml/min:
- ampicillin 2g IV q4h x4-6wk
- penicillin G 18-30M units IV q24h x4-6wk
- gentamicin 3mg/kg in 3 divided doses x4-6wk

CrCl <50ml/min:
ampicillin 2g IV q4h + ceftriaxone 2g IV q12h x6wk
**** resistant to penicillin or vancomycin
vancomycin resistant (VRE):
- daptomycin 10-12 mg/kg x6wk
- linezolid 600 mg q12h x6wk

penicillin resistant:
vancomycin 30mg/kg in 2 divided doses x6wk + gentamicin 3mg/kg in 3 divided doses x6wk
* CNS infections
** Bacterial meningitis
*** causes
**** common pathogens
1. S. pneumoniae 
2. N. meningitis
3. Group B Streptococci---Streptococcus agalactiae
4. L. monocytogenes 
5. H. influenzae
**** [#A] neonates---(0, 1) months
- Strep. agalactiae
- Gram-(-) enterics
- Listeria monocytogenes
**** [#A] (1, 23] months
- Strep. agalactiae
- Neisseria meningitidis
- Strep. pneumoniae
- Haemophilus influenzae
**** [#A] (2, 50] years
- Neisseria meningitidis
- Step. pneumoniae
**** [#A] (50, ∞) years
- Strep. pneumoniae
- Neisseria meningitidis
- Gram-(-) enterics
- Listeria monocytogenes
*** diagnosis
**** [#A] triad of symptoms
- Fever
- AMS
- Nuchal rigidity---aka neck stiffness 
**** [#A] abnormal CSF evaluation
- CSF opening pressure: elevated, >180 mm H_2O
- WBC: elevated
- *differential: PMNs---neutrophils*
- protein: elevated; >100-500 mg/dL
- CSF blood glucose: decreased; <40%
*** [#B] empiric treatment
**** age <1 month
- ampicillin + cefotaxime
- ampicillin + aminoglycoside
**** age 1-23 months
vancomycin + 3rd generation cephalosporin (cefotaxime or ceftriaxone)
**** age 2-50 yrs
vancomycin + 3rd generation cephalosporin (cefotaxime or ceftriaxone)
**** age >50 yrs
Vancomycin + ampicillin + 3rd generation cephalosporin (cefotaxime or ceftriaxone)
Ampicillin is added for Listeria coverage
*** targeted treatment (drug, dose, frequency)
**** [#B] N. meningitidis
1. ceftriaxone 2g q12h 
2. meropenem 2g q8h
3. ampicillin 2g q4h
***** [#A] duration
7-10 days
**** [#A] Pseudomonas
- Zosyn
- cefepime
- ceftazidime
**** S. pneumoniae
***** [#A] PCN sensitive strains
1. ampicillin 2g q4h
2. penicillin G 4mu q4h
***** [#A] intermediate strains
1. ceftriaxone 2g q12h
2. cefotaxime 2g q6h
***** [#A] duration
10-14 days
**** L. monocytogenes
{ampicillin 2g q4h, penicillin G 4mu q4h} ± gentamicin 2 mg/kg q8h
***** [#A] duration
21 days
**** H. influenzae
***** β-lactamase negative
ampicillin 2g q4h
***** β-lactamase positive
- ceftriaxone 2g q12h
- cefotaxime 2g q6h
***** [#A] duration
7 days
**** S. agalactiae
{ampicillin 2g q4h, penicillin G 4 mu q4h} ± genatmicin 2mg/kg q8h
**** S. epidermidis
***** MSSA
- naficillin 2g q4h
- oxacillin 2g q4h
***** [#B] MRSA
- vancomycin 30-60 mg/kg/day q8h
- linezolid 600mg q12h
**** [#A] viral meningitis
acyclovir 10 mg/kg IV q8h then transition to 800mg PO 5x per day
*** [#A] use of corticosteroids
dexamethasone
** Brain abscess
*** empiric treatment
- 3rd or 4th gen CFN + vanc + metronidazole
- Vanc + meropenem 
- Vanc + piperacillin/tazobactam
** Viral meningitis
acyclovir 10 mg/kg IV q8h
** Encephalitis
** Infectious thrombophlebitis
* multi-drug resistance
** [#A] most common
ESCAPED; ESC ⇒ Gram-(+), APED ⇒ Gram-(-)
- Enterococci
- Staphylococci and Streptococci
- Clostridium difficile
- Acinetobacter  spp.
- Pseudomonas aeurginosa
- Enterobacteriaceae
- Neisseria gonorrhoeae
** [#B] mechanisms of resistance
- expulsion of the antibiotic before it can reach the target
  - blocking entry; ↓ membrane permeability or porin mutations
  - efflux pump
- alteration or loss of antibiotic target
- enzymatic activation (β lactamases)
*** VRE (Vancomycin Resistant Enterococcus)
modification of cell wall terminal peptide resulting in a 1000x lower affinity of vancomycin binding; AlaAla → LacSer
*** Staphylococcus aureus
- β-lactamases (penicillinases) inactivate the β-lactam ring of penicillin, rendering them ineffective against the organism
- mecA gene encoding for PBP-2a, which has decreased affinity to β-lactams
*** VISA
thickening of cell wall; less autolysis, less availability for intracellular target; more AlaAla binds vancomycin
*** VRSA
vanA gene synthesizes an alternative cell wall terminal peptide to which vancomycin is unable to bind
*** Streptococci
- chemical modification of the ribosomal target
- active efflux pumps
** treatment
*** [#A] VRE
linezolid (Zyvox) 600 mg IV/PO BID
*** [#B] CA-MRSA (community acquired MRSA)
- clindamycin
- Bactrim
- doxycycline/minocycline
- vancomycin (for severe infections only)

/not recommended/:
- fluroquinolones
- macrolides
*** [#A] N. gonorrhea
ceftriaxone 250mg IM x1 + {azithromycin 1g x1, doxycycline 100mg BID x7}
** VISA
vancomycin intermediate S. aureus
*** at risk
prior vancomycin exposure with serum concentraitons consistenly <10mg/dL
** [#A] CDC Four Core Actions---strategies for preventing resistance
1. preventing infections; preventing the spread of resistance
2. tracking
3. improving antibiotic prescribing/stewardship
4. developing new drugs and diagnostic tests
* C. difficile
** [#A] risk factors
- Advanced age
- drugs
  - PPI or laxative use
  - Antibiotic use 
- hospital stay
  - GI surgery or manipulation of GI tract (eg, tube feeding)
  - Cancer chemotherapy
** [#A] antibiotic culprits
- Clindamycin
- Cephalosporins (3rd/4th gen)
- Carbapenems
- Fluroquinolone
** [#C] pathophysiology
- Gram-(+) spore-forming anaerobic bacillus
- causes a toxin-mediated disease
- toxins A (enterotoxin) and B (cytotoxin), causing damage to colonic mucosa
** [#B] treatment
- vancomycin 125mg PO QID x10d
- fidaxomicin 200mg PO BID x10d
*** initial episode, fulminant
vancomycin PO 500mg QID + metronidazole 500mg IV q8h
** [#A] clinical definitions
*** initial episode, non-severe
WBC <= 15k and SCr <= 1.5
*** initial episode, severe
WBC > 15k or SCr > 1.5
*** initial episode, fulminant
- hypotension or shock
- ileus
- megacolon
** [#B] measures to prevent and control CDI
- medical/hospital hygiene
- chlorine wipes
- antimicrobial stewardship (restrict use of cephalosporin and Clindamycin)
* sepsis
** [#A] terminology
*** systemic inflammatory response syndrome (SIRS)
2 or more of...
- temperature >100.4 °F
- HR >90
- RR >20
- PaCO_2 <32
- WBC >12k
- immature (band) forms >10%
*** septic shock
- subset of sepsis with circulatory dysfunction associated with a higher risk of mortality
- signs of sepsis plus hypotension (MAP <70 or SBP <90)
** [#A] timeframe
first 3 hrs, then 6 hours to add presssor
** [#A] treatment
3 hours bundle:
1. lactate
2. blood cultures
3. broad spectrum antibiotics
4. fluids 30ml/kg (NS or LR) for hypotension or ≥ 4 lactate
6 hours bundle:
1. repeat lactate if initially elevated
2. vasopressor (norepinephrine) if MAP <65
** [#B] steroids
- IV hydrocortisone 200 mg/d is only recommended when fluid resuscitation and vasopressor therapy fail to achieve hemodynamic stability
- /for septic shock only/, not sepsis
** remarks
*** [#B] daptomycin
don’t use if the patient has pneumonia
* bloodstream infections
** [#A] risk factors
- catheterization
- S. aureus nasal colonization
- underlying disease
- occlusive transparent dressing
** [#A] most common pathogen
S. aureus
** [#A] treatment
- drug of choice: vancomycin 15-20mg/kg IV q8-12hr; goal trough 15-20 mcg/ml
- daptomycin 4-6mg/kg q24h
- /do not use linezolid/
- always cover for MRSA
* misc/trivia
** [#A] structure → drug or drug class
*** <img src="https://upload.wikimedia.org/wikipedia/commons/thumb/2/24/Cefotaxime.svg/1200px-Cefotaxime.svg.png"/>
3rd generation cephalosporin (cefotaxime); you can tell by the 2-amino-1,3-thiazole ring and the oxime functional group
** [#B] infection → drugs
*** MRSA
- Bactrim
- Ceftaroline (5th gen)
- vancomycin
- daptomycin Clindamycin
- tetracycline
- Streptogramins (Q/D)
- Mupirocin
- Linezolid
- Tigecycline
*** P. aeruginosa
- ceftazidime
- cefepime
- carbapenems
- ciprofloxacin
- gentamycin
- amikacin
- combos
  - Zosyn
  - Timentin
  - Avicaz
  - Zerbaxa
*** C. difficile
- vancomycin
- metronidazole
- fidaxomicin
*** VRE
- daptomicin
- linezolid
- streptogramins
*** CRE
- Zerbaxa
- Avicaz
*** ESBL
5th generation cephalosporins + carbapenems
** bactericidal vs. bacteriostatic
*** bactericidal drugs
- Vancomycin
- Fluoroquinolones
- Penicillin
- Aminoglycosides
- Cephalosporins
- Metronidazole
*** bacteriostatic drugs
- Erythromycin
- Clindamycin
- Sulfamethoxazole
- Trimethoprim
- Tetracyclines
- Chloramphenicol
** moxifloxacin
not a drug for UTIs
** no coverage against strep pneumoniae
Cipro
** renal impairment antibiotics
*** individual drugs
- nitrofurantoin
- piperacillin/tazobactam
- Bactrim
- tetracycline
- ciprofloacin
- amoxicillin
- cefuroxime
- cephalexin
- vancomycin
- daptomycin
- gentamycin
*** [#A] by class
- Penicillins and Cephalosporins
- Fluroquinolones
- Aminoglycosides
- Sulfonamides & Trimethoprim
- daptomycin
- Tetracyclines (except doxy & mino)
- Nitrofurantoin
- Chloramphenicol
- Clindamycin
- Pyrazinamide
